These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 24765829

  • 21. Repeatability of high-frequency distortion-product otoacoustic emissions in normal-hearing adults.
    Dreisbach LE, Long KM, Lees SE.
    Ear Hear; 2006 Oct; 27(5):466-79. PubMed ID: 16957498
    [Abstract] [Full Text] [Related]

  • 22. Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients.
    Eiamprapai P, Yamamoto N, Hiraumi H, Ogino-Nishimura E, Kitamura M, Hirano S, Ito J.
    Laryngoscope; 2012 Jun; 122(6):1392-6. PubMed ID: 22555987
    [Abstract] [Full Text] [Related]

  • 23. [Distortion product otoacoustic emission test of cochlear deafness].
    Liu A, Cui Y, Ge X, Wang C.
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 Oct; 17(10):588-90. PubMed ID: 14727425
    [Abstract] [Full Text] [Related]

  • 24. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
    Dhooge I, Dhooge C, Geukens S, De Clerck B, De Vel E, Vinck BM.
    Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
    [Abstract] [Full Text] [Related]

  • 25. Distortion-product otoacoustic emissions and cochlear microphonics: relationships in patients with and without endolymphatic hydrops.
    Fetterman BL.
    Laryngoscope; 2001 Jun; 111(6):946-54. PubMed ID: 11404602
    [Abstract] [Full Text] [Related]

  • 26. Results for audiology and distortion product and transient evoked otoacoustic emissions in patients with systemic lupus erythematosus.
    Karabulut H, Dagli M, Ates A, Karaaslan Y.
    J Laryngol Otol; 2010 Feb; 124(2):137-40. PubMed ID: 19852869
    [Abstract] [Full Text] [Related]

  • 27. The protective effect of intratympanic dexamethasone on streptomycin ototoxicity in rats.
    Gül A, Şengül E, Yılmaz B, Özkurt FE, Akdağ M, Keleş A, Topçu İ.
    Ear Nose Throat J; 2017 Jun; 96(6):E12-E17. PubMed ID: 28636736
    [Abstract] [Full Text] [Related]

  • 28. Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis.
    Vasconcelos KA, Frota SMMC, Ruffino-Netto A, Kritski AL.
    J Bras Pneumol; 2018 Apr; 44(2):85-92. PubMed ID: 29791559
    [Abstract] [Full Text] [Related]

  • 29. [Examinations of distortion product otoacoustic emission in hereditary progressive non-syndromic hearing loss].
    Ke X, Yu H, Liu Y, Gu Z, Lu Y, Li L.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2000 Apr; 35(2):102-4. PubMed ID: 12768663
    [Abstract] [Full Text] [Related]

  • 30. Effect of tinnitus on distortion product otoacoustic emissions varies with hearing loss.
    Husain FT.
    Am J Audiol; 2013 Jun; 22(1):125-34. PubMed ID: 23800808
    [Abstract] [Full Text] [Related]

  • 31. The effect of treatment with vincristine on transient evoked and distortion product otoacoustic emissions.
    Riga M, Psarommatis I, Korres S, Lyra Ch, Papadeas E, Varvutsi M, Ferekidis E, Apostolopoulos N.
    Int J Pediatr Otorhinolaryngol; 2006 Jun; 70(6):1003-8. PubMed ID: 16359737
    [Abstract] [Full Text] [Related]

  • 32. Hearing threshold estimation using concurrent measurement of distortion product otoacoustic emissions and auditory steady-state responses.
    Rosner T, Kandzia F, Oswald JA, Janssen T.
    J Acoust Soc Am; 2011 Feb; 129(2):840-51. PubMed ID: 21361442
    [Abstract] [Full Text] [Related]

  • 33. Effect of cisplatin chemotherapy on the inner ear function and serum prestin concentration.
    Jalali MM, Saedi HS, Saadat F.
    Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):2783-2789. PubMed ID: 34213608
    [Abstract] [Full Text] [Related]

  • 34. Objective evaluation of the effects of intravenous lidocaine on tinnitus.
    Kalcioglu MT, Bayindir T, Erdem T, Ozturan O.
    Hear Res; 2005 Jan; 199(1-2):81-8. PubMed ID: 15574302
    [Abstract] [Full Text] [Related]

  • 35. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA).
    Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M.
    J Rehabil Res Dev; 2014 Jan; 51(1):81-100. PubMed ID: 24805896
    [Abstract] [Full Text] [Related]

  • 36. Distortion product otoacoustic emissions during the first year in term infants: a longitudinal study.
    Zang Z, Jiang ZD.
    Brain Dev; 2007 Jul; 29(6):346-51. PubMed ID: 17113742
    [Abstract] [Full Text] [Related]

  • 37. DPOAE in estimation of the function of the cochlea in tinnitus patients with normal hearing.
    Sztuka A, Pospiech L, Gawron W, Dudek K.
    Auris Nasus Larynx; 2010 Feb; 37(1):55-60. PubMed ID: 19560298
    [Abstract] [Full Text] [Related]

  • 38. [Monitoring drug ototoxicity with distortion products].
    Orts Alborch M, Morant Ventura A, García Callejo J, Ferrer Baixauli F, Martínez Beneito MP, Marco Algarra J.
    Acta Otorrinolaringol Esp; 2000 Feb; 51(5):387-95. PubMed ID: 11000679
    [Abstract] [Full Text] [Related]

  • 39. Short-term changes of hearing and distortion product otoacoustic emissions in sudden sensorineural hearing loss.
    Park H, Lee Y, Park M, Kim J, Na B, Shin J.
    Otol Neurotol; 2010 Aug; 31(6):862-6. PubMed ID: 20601916
    [Abstract] [Full Text] [Related]

  • 40. [Monitoring ototoxic side effects in streptomycin therapy of tuberculosis patients with transitory evoked otoacoustic emissions TEOAE].
    Fürst G, Maurer J, Schlegel J.
    Pneumologie; 1995 Nov; 49(11):590-5. PubMed ID: 8584531
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.